[HONG KONG, March 8, 2023] BPI US West, the world's top biopharmaceutical event, was successfully held in San Diego, USA. The event brings together more than 1000 global scientists, 90 exhibitors, and about 125 scientific case studies across 6 sections.

BPI US West 2023

In this year’s section of "Cell Line Development and Engineering", scientists from Pfizer, Atum Bio, Merck, and MacroGenics all focused on the benefits of site-specific integration (hereinafter referred to as “SSI”) technology in cell line development. It was noted that SSI technology has already been used in IND filing and listing for several new drugs. Especially Dr. Michael Chen, CEO of Great Bay Bio (hereinafter referred to as “GBB”), delivered the latest progress on the commercial SSI platform in GBB.

GBB pioneered the integration of artificial intelligence technology into SSI development, innovatively provided a commercialized AI + SSI platform, AlfaCell^®. With the high comparability between the cell pool and monoclone cell, engineers can predict the titer and quality from the results of cell pool in less than 6 weeks, afterwards, only one 96-well plate and 8 weeks are needed to obtain the monoclones. The application case study data also showed that the AlfaCell^® platform can reach product expression levels of as high as 12g/L and maintain stable production for more than 90 days. As a commercial platform, GBB’s AlfaCell^® platform provides various services, including DNA to RCB, cell line license-out and co-development.